Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Hemopurifier Bird Flu Update

 

 

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Hemopurifier Bird Flu Update

 

Investorideas.com (www.investorideas.com) a go-to platform for big investing ideas for stock traders, including  biotech  and medical tech stocks reports on trading and news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

The stock has had big gains in this morning’s trading session following an update on the company’s Hemopurifier device in the treatment of Bird Flu.

 

The stock is trading at $0.5761, up 0.1427, gaining 32.7745% on volume of over 55 Million shares as of this report. The stock had a day’s high of $0, 8275. 

 

Today Aethlon provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."

 

Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including a case of severe infection in Louisiana, and yesterday's declaration of a state of emergency in California.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/12201AEMD-Hemopurifier-Bird-Flu-Update.asp

 

The Aethlon Hemopurifier is an investigational extracorporeal medical device designed to remove enveloped viruses and extracellular vesicles from the bloodstream. The device incorporates plasma separation, size exclusion, and affinity binding to a proprietary resin containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a medical grade diatomaceous earth. Enveloped viruses and extracellular vesicles contain the sugar mannose on their surface, which is the therapeutic target of the GNA.

 

Aethlon has previously contracted Battelle labs to examine the in vitro removal of influenza viruses including H5N1 by a scaled down version of the Aethlon Hemopurifier. In this experiment, cell culture media was spiked with the H5N1 virus and continuously circulated over the device. Samples were taken periodically to examine viral removal by the device. In this study, a miniature version of the device removed 99% of H5N1 following 6 hours of treatment.

 

While the Aethlon Hemopurifier has not yet been used to treat patients with severe influenza, including those infected with H5N1, it has been used in 38 patients across 164 distinct treatment sessions, targeting diseases such as hepatitis C, HIV, and in patients critically ill due to COVID-19 and Ebola. The Hemopurifier has a "breakthrough device" designation with the FDA for life-threatening viruses for which there is no effective treatment.

 

Current treatment guidelines from the Center for Disease Control and Prevention (https://www.cdc.gov/bird-flu/hcp/novel-av-treatment-guidance/), for hospitalized patients with suspected Bird Flu (H5N1), are to initiate antiviral therapy as soon as possible with Oseltamivir, with or without combination therapy with Baloxavir. Clinical failures during Oseltamavir therapy due to the development of antiviral resistance have been observed in hospitalized patients with H5N1. This phenomenon raises the possibility that novel treatment strategies may be required. Aethlon Medical will monitor this situation closely and interact with hospitals, the state of California, and the FDA as appropriate if cases mount and currently available treatments are not effective.

 

Recent news

https://www.investorideas.com/news/2024/12201AEMD-Hemopurifier-H5N1-Bird-Flu.asp

 

Biotech stocks to watch:

Research more Biotech and medical technology stocks with Investorideas.com free stock directory

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: This news alert for AEMD is part of Investorideas.com paid content on behalf of Aethlon Medical. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, IR, PR and social media, podcast sponsorship and ticker tag content creation services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about digital advertising and guest posts/sponsored posts

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

 

Contact Investorideas.com

800 665 0411